# OnCo record paper-ino-vate-inotuzumab-all-nejm-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ino-vate-inotuzumab-all-nejm-2016" ;
  schema:name "INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL"@en ;
  schema:description "A CD22 antibody-drug conjugate produced complete remission in 81% of adults with relapsed ALL compared with 29% on chemotherapy, at the cost of liver toxicity in about one in ten."@en ;
  schema:url <https://onco.cc/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1509277>, <https://clinicaltrials.gov/study/NCT01564784> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1509277> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Kantarjian HM, DeAngelo DJ, Stelljes M, et al." ;
  onco:related <https://onco.cc/pairings/inotuzumab-then-transplant-caution/> ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:targets <https://onco.cc/targets/cd22/> ;
  onco:drugs <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/drugs/blinatumomab/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/os/> ;
  onco:people <https://onco.cc/people/hagop-kantarjian/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:journals <https://onco.cc/journals/nejm/> .